B-cell adult acute lymphocytic leukemia

Summary

B-cell adult acute lymphocytic leukemia (MONDO:0000814) is a cancer with 1 cohort gene (1 CIViC-evidence somatic driver) and 110 clinical trials. Molecularly, FLT3 Overexpression confers sensitivity to Sunitinib in B-cell Adult Acute Lymphocytic Leukemia (CIViC Level C). Top therapeutic interventions include mercaptopurine anhydrous, blinatumomab, and pegaspargase.

At a glance

• Classification: Cancer
• Cohort genes: 1
• Clinical trials: 110
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	B-cell adult acute lymphocytic leukemia
Mondo ID	MONDO:0000814
EFO	EFO:1001935
DOID	DOID:0060592
NCIT	C9143
UMLS	C0279593
MedGen	79010
GARD	0022832
Is cancer (heuristic)	yes

Also known as: adult B acute lymphoblastic leukemia · adult B cell acute lymphoblastic leukaemia · adult B cell acute lymphoblastic leukemia · adult B cell acute lymphocytic leukaemia · adult B cell acute lymphocytic leukemia · adult B cell ALL · adult B-cell acute lymphoblastic leukemia · adult B-cell acute lymphocytic leukaemia · adult B-cell acute lymphocytic leukemia · adult B-cell ALL · adult B-cell childhood acute lymphoblastic leukaemia · adult B-cell childhood acute lymphoblastic leukemia · adult precursor B-lymphoblastic leukaemia · adult precursor B-lymphoblastic leukemia · B acute lymphoblastic leukaemia · B acute lymphoblastic leukemia · B cell adult acute lymphoblastic leukaemia · B cell adult acute lymphoblastic leukemia · B cell adult acute lymphocytic leukaemia · B cell adult acute lymphocytic leukemia (+6 more)

Data availability: 137 cell lines.

Disease family

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › acute lymphoblastic leukemia › adult acute lymphoblastic leukemia › B-cell adult acute lymphocytic leukemia

Related subtypes (1): T-cell adult acute lymphocytic leukemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
FLT3	Act	ALL,AML	CIViC #24

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
FLT3	Orphanet:102724	Acute myeloid leukemia with t(8;21)(q22;q22) translocation
FLT3	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
FLT3	Orphanet:589534	Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2)
FLT3	Orphanet:589595	Mixed phenotype acute leukemia with t(v;11q23.3)
FLT3	Orphanet:98829	Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
FLT3	Orphanet:98832	Acute myeloid leukemia with minimal differentiation
FLT3	Orphanet:98833	Acute myeloblastic leukemia without maturation
FLT3	Orphanet:98834	Acute myeloblastic leukemia with maturation
FLT3	Orphanet:99861	Precursor T-cell acute lymphoblastic leukemia

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
FLT3	HGNC:3765	ENSG00000122025	P36888	Receptor-type tyrosine-protein kinase FLT3	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
FLT3	Receptor-type tyrosine-protein kinase FLT3	Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
FLT3	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cerebellar cortex	1
cerebellar hemisphere	1
male germ line stem cell (sensu Vertebrata) in testis	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
FLT3	166	broad	marker	male germ line stem cell (sensu Vertebrata) in testis, cerebellar hemisphere, cerebellar cortex

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
FLT3	3,570

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
FLT3	P36888	11

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 27. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
FLT3 mutants bind TKIs	1	11420.0×	2e-04	FLT3
KW2449-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
semaxanib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
crenolanib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
gilteritinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
lestaurtinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
midostaurin-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
pexidartinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
ponatinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
quizartinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
sorafenib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
sunitinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
tandutinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
linifanib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
tamatinib-resistant FLT3 mutants	1	11420.0×	2e-04	FLT3
STAT5 Activation	1	1631.4×	9e-04	FLT3
FLT3 signaling through SRC family kinases	1	1631.4×	9e-04	FLT3
FLT3 signaling by CBL mutants	1	1631.4×	9e-04	FLT3
STAT5 activation downstream of FLT3 ITD mutants	1	1142.0×	0.001	FLT3
Signaling by FLT3 ITD and TKD mutants	1	761.3×	0.002	FLT3
Negative regulation of FLT3	1	713.8×	0.002	FLT3
FLT3 Signaling	1	346.1×	0.004	FLT3
PI3K Cascade	1	271.9×	0.004	FLT3
Constitutive Signaling by Aberrant PI3K in Cancer	1	126.9×	0.009	FLT3
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	96.8×	0.011	FLT3
PIP3 activates AKT signaling	1	66.8×	0.016	FLT3
RAF/MAP kinase cascade	1	61.1×	0.016	FLT3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
leukocyte homeostasis	1	5617.3×	0.002	FLT3
pro-B cell differentiation	1	4213.0×	0.002	FLT3
myeloid progenitor cell differentiation	1	2407.4×	0.002	FLT3
lymphocyte proliferation	1	2407.4×	0.002	FLT3
common myeloid progenitor cell proliferation	1	1872.4×	0.002	FLT3
dendritic cell differentiation	1	1053.2×	0.003	FLT3
positive regulation of tyrosine phosphorylation of STAT protein	1	732.7×	0.004	FLT3
positive regulation of MAP kinase activity	1	648.1×	0.004	FLT3
cellular response to glucocorticoid stimulus	1	624.1×	0.004	FLT3
cellular response to cytokine stimulus	1	543.6×	0.004	FLT3
liver regeneration	1	510.7×	0.004	FLT3
peptidyl-tyrosine phosphorylation	1	421.3×	0.004	FLT3
hemopoiesis	1	267.5×	0.006	FLT3
B cell differentiation	1	218.9×	0.007	FLT3
cell surface receptor protein tyrosine kinase signaling pathway	1	173.7×	0.008	FLT3
protein autophosphorylation	1	145.3×	0.009	FLT3
cytokine-mediated signaling pathway	1	130.6×	0.010	FLT3
regulation of apoptotic process	1	83.4×	0.014	FLT3
positive regulation of MAPK cascade	1	80.6×	0.014	FLT3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1	78.4×	0.014	FLT3
cell migration	1	61.5×	0.017	FLT3
positive regulation of cell population proliferation	1	33.6×	0.030	FLT3

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
FLT3	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
FLT3	143	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PONATINIB	4	FLT3
AFATINIB	4	FLT3
FEDRATINIB	4	FLT3
TIVOZANIB	4	FLT3
AXITINIB	4	FLT3
SORAFENIB	4	FLT3
NERATINIB	4	FLT3
INFIGRATINIB PHOSPHATE	4	FLT3
INFIGRATINIB	4	FLT3
IBRUTINIB	4	FLT3
PALBOCICLIB	4	FLT3
REGORAFENIB	4	FLT3
ENTRECTINIB	4	FLT3
PACRITINIB	4	FLT3
FOSTAMATINIB	4	FLT3
QUIZARTINIB DIHYDROCHLORIDE	4	FLT3
CABOZANTINIB	4	FLT3
CERITINIB	4	FLT3
VANDETANIB	4	FLT3
NILOTINIB	4	FLT3
BOSUTINIB	4	FLT3
FILGOTINIB	4	FLT3
ABEMACICLIB	4	FLT3
GILTERITINIB	4	FLT3
BRIGATINIB	4	FLT3
PEXIDARTINIB	4	FLT3
PRALSETINIB	4	FLT3
PAZOPANIB	4	FLT3
NINTEDANIB	4	FLT3
SUNITINIB	4	FLT3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
FLT3	3,132	Binding:3096, Functional:24, ADMET:8, Toxicity:4

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
FLT3	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
FLT3	3,132

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

29 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
PONATINIB	4	FLT3
AFATINIB	4	FLT3
FEDRATINIB	4	FLT3
TIVOZANIB	4	FLT3
AXITINIB	4	FLT3
SORAFENIB	4	FLT3
NERATINIB	4	FLT3
INFIGRATINIB PHOSPHATE	4	FLT3
INFIGRATINIB	4	FLT3
PALBOCICLIB	4	FLT3
REGORAFENIB	4	FLT3
ENTRECTINIB	4	FLT3
PACRITINIB	4	FLT3
FOSTAMATINIB	4	FLT3
QUIZARTINIB DIHYDROCHLORIDE	4	FLT3
CABOZANTINIB	4	FLT3
CERITINIB	4	FLT3
VANDETANIB	4	FLT3
NILOTINIB	4	FLT3
BOSUTINIB	4	FLT3
FILGOTINIB	4	FLT3
ABEMACICLIB	4	FLT3
GILTERITINIB	4	FLT3
BRIGATINIB	4	FLT3
PEXIDARTINIB	4	FLT3
PRALSETINIB	4	FLT3
PAZOPANIB	4	FLT3
NINTEDANIB	4	FLT3
SUNITINIB	4	FLT3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	FLT3
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 110.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	35
PHASE2	32
PHASE1/PHASE2	23
PHASE3	9
Not specified	6
EARLY_PHASE1	3
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02618109	PHASE4	TERMINATED	Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
NCT02101853	PHASE3	ACTIVE_NOT_RECRUITING	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT03007147	PHASE3	ACTIVE_NOT_RECRUITING	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03150693	PHASE3	RECRUITING	Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03914625	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03937544	PHASE2/PHASE3	RECRUITING	Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
NCT03959085	PHASE3	RECRUITING	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT05602194	PHASE3	ACTIVE_NOT_RECRUITING	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT00075725	PHASE3	COMPLETED	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT00671034	PHASE3	COMPLETED	Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT02883049	PHASE3	COMPLETED	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT00792948	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
NCT01371630	PHASE1/PHASE2	RECRUITING	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT02143414	PHASE2	ACTIVE_NOT_RECRUITING	Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
NCT02877303	PHASE2	RECRUITING	Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
NCT02981628	PHASE2	RECRUITING	Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT03441061	PHASE2	ACTIVE_NOT_RECRUITING	Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
NCT03504644	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
NCT03739814	PHASE2	RECRUITING	Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
NCT04546399	PHASE2	RECRUITING	A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT05281809	PHASE2	RECRUITING	Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
NCT05303792	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
NCT05310591	PHASE1/PHASE2	RECRUITING	Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
NCT06124157	PHASE2	RECRUITING	A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06317662	PHASE2	RECRUITING	Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06703216	PHASE1/PHASE2	NOT_YET_RECRUITING	Pre-emptive Anakinra for Cytokine Event Reduction
NCT00052520	PHASE1/PHASE2	COMPLETED	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
NCT00061945	PHASE1/PHASE2	COMPLETED	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00867529	PHASE2	COMPLETED	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
NCT00873093	PHASE2	COMPLETED	Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT00918333	PHASE1/PHASE2	COMPLETED	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
NCT01093586	PHASE2	COMPLETED	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01258998	PHASE2	COMPLETED	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
NCT01326702	PHASE1/PHASE2	COMPLETED	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
NCT01670084	PHASE2	WITHDRAWN	Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01735604	PHASE1/PHASE2	UNKNOWN	Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
NCT01769209	PHASE2	COMPLETED	Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02129062	PHASE2	TERMINATED	Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT02281279	PHASE1/PHASE2	WITHDRAWN	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
NCT02420717	PHASE2	TERMINATED	Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MERCAPTOPURINE ANHYDROUS	4	42
BLINATUMOMAB	4	16
PEGASPARGASE	4	14
INOTUZUMAB OZOGAMICIN	4	13
THIOGUANINE	4	12
CALASPARGASE PEGOL	4	8
DAUNORUBICIN	4	8
ASPARAGINASE	4	5
ASPARAGINASE ERWINIA CHRYSANTHEMI	4	4
DASATINIB ANHYDROUS	4	4
HYDROCORTISONE SODIUM SUCCINATE	4	4
IMATINIB	4	4
DEXRAZOXANE	4	3
LEUCOVORIN	4	3
MITOXANTRONE	4	3
VINCRISTINE	4	3
2-MERCAPTOETHANESULFONIC ACID	4	2
ALDESLEUKIN	4	2
ALLOPURINOL	4	2
BENDAMUSTINE HYDROCHLORIDE	4	2
LEVOLEUCOVORIN	4	2
ACYCLOVIR	4	1
ALEMTUZUMAB	4	1
CLOFARABINE	4	1
CYTARABINE	4	1
ETOPOSIDE PHOSPHATE	4	1
FLUDARABINE PHOSPHATE	4	1
HYDROCORTISONE	4	1
IBRUTINIB	4	1
IFOSFAMIDE	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 3 prognostic, 2 diagnostic.

Molecular subtype	Therapy	Effect	Level	CIViC
FLT3 Overexpression	Sunitinib	Sensitivity/Response	CIViC C	EID1528